Repurposing existing drugs for COVID-19: an endocrinology perspective
September 2020
in “BMC Endocrine Disorders”
TLDR Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.
The document from September 29, 2020, explores the possibility of using existing drugs to treat COVID-19, with a focus on the field of endocrinology. It identifies that COVID-19 can lead to worse outcomes in individuals with certain conditions such as aging, uncontrolled diabetes, and obesity. The paper points out the significance of the renin-angiotensin-aldosterone system (RAAS), angiotensin-converting enzyme-2 (ACE2), and TMPRSS2 in the virus's infectivity. Dexamethasone, a glucocorticoid, was the only drug with emerging evidence for treating severely affected COVID-19 patients at the time. Other drugs like anti-androgens, statins, and ACE inhibitors were considered for their potential effects but lacked specific evidence for COVID-19 treatment. The document concludes that while dexamethasone may reduce mortality in severely ill patients, other treatments should be limited to clinical research studies until their efficacy is proven, and emphasizes the need for clinical trials to establish the efficacy of these drugs in treating COVID-19.
View this study on bmcendocrdisord.biomedcentral.com →
Cited in this study
research Anti‐androgens may protect against severe COVID‐19 outcomes: results from a prospective cohort study of 77 hospitalized men
Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
research What does androgenetic alopecia have to do with COVID‐19? An insight into a potential new therapy
Androgenetic alopecia linked to COVID-19 severity; drugs reducing androgen receptor activation may help.
research A preliminary observation: Male pattern hair loss among hospitalized COVID‐19 patients in Spain – A potential clue to the role of androgens in COVID‐19 severity
Male pattern hair loss could hint at androgens affecting COVID-19 severity.
research Racial variations in COVID‐19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti‐androgens a potential treatment for COVID‐19?
Genetic differences may affect COVID-19 deaths; anti-androgens could be potential treatment.
research Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
research Safety concerns when using novel medications to treat alopecia
Consider benefits and risks of new alopecia treatments for safety.
research Studying the correlation of renin-angiotensin-system (RAS) components and insulin resistance in polycystic ovary syndrome (PCOs)
The study found a significant link between the renin-angiotensin system and insulin resistance in women with polycystic ovary syndrome.